{"id":"lower-dose-atropine-sulfate-eye-drops","safety":{"commonSideEffects":[{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Mild pupil dilation"},{"rate":null,"effect":"Ocular irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atropine is an anticholinergic agent that inhibits accommodation and pupil constriction by antagonizing M1 and M3 muscarinic receptors. At lower doses (typically 0.01%), it retains myopia-slowing efficacy while minimizing pupil dilation and accommodation paralysis side effects associated with conventional higher-dose formulations. The exact mechanism of myopia control remains incompletely understood but involves both accommodation-dependent and accommodation-independent pathways.","oneSentence":"Low-dose atropine competitively blocks muscarinic acetylcholine receptors in the eye to slow myopia progression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:39.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myopia progression control in children"}]},"trialDetails":[{"nctId":"NCT06209281","phase":"PHASE3","title":"A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-05-13","conditions":"Myopia","enrollment":526},{"nctId":"NCT06209320","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-03-15","conditions":"Myopia","enrollment":777}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lower dose atropine sulfate","Eye drops"],"phase":"phase_3","status":"active","brandName":"Lower dose atropine sulfate eye drops","genericName":"Lower dose atropine sulfate eye drops","companyName":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","companyId":"zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose atropine competitively blocks muscarinic acetylcholine receptors in the eye to slow myopia progression. Used for Myopia progression control in children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}